Safety and efficacy of PEACH

Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH)

Laure Peter-Derex, Frédéric Philippeau, Pierre Garnier, Nathalie André-Obadia, Sébastien Boulogne, Hélène Catenoix, Philippe Convers, Laure Mazzola, Michel Gouttard, Maud Esteban, Julia Fontaine, Laura Mechtouff, Elodie Ong, Tae-Hee Cho, Norbert Nighoghossian, Nathalie Perreton, Anne Termoz, Julie Haesebaert, Anne-Marie Schott, Muriel Rabilloud, Christine Pivot, Carole Dhelens, Andrea Filip, Yves Berthezène, Sylvain Rheims, Florent Boutitie, Laurent Derex

An article produced within RESHAPE published in the Lancet Neurology in 2022.

Lancet Neurol. 2022 Sep;21(9):781-791

Abstract :


The PEACH study, carried out within RESHAPE, received on April 5, 2023 the prize for excellence in neurology awarded by the French Society of Neurology.
This prize rewards the best French clinical research publications of the year 2022
This study funded by a PHRC-Inter-regional was published in the Lancet Neurology in 2022.
Its results showed the frequency of early epileptic seizures in patients with intracerebral hemorrhage, these seizures generally not being diagnosed by the nursing staff but revealed by continuous EEG recording, and the possibility of preventing them by a medical treatment.
The PEACH 2 study is now planned to demonstrate the benefit on the functional prognosis of patients of an anti-epileptic treatment administered in the acute phase of intracerebral hemorrhage.

 

DOI : 10.1016/S1474-4422(22)00235-6     PMID : 35963261

See publication

Chargement en cours...